1
|
Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Windschilt HE, Zhao X, Loprinzi CL. Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: Results from a placebo-controlled phase III trial. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4025] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4025 Background: Cumulative sNT is the dose-limiting toxicity of oxaliplatin which commonly leads to early discontinuation of oxaliplatin-based therapy in the palliative and adjuvant setting. We recently demonstrated the protective effect of CaMg against oxaliplatin-induced sNT as assessed by NCI-CTC (Nikcevich ASCO 2008). It is unclear, though, if CaMg reduced acute and/or chronic, cumulative sNT. Methods: 104 pts with colon cancer undergoing adjuvant therapy with FOLFOX were randomized to IV CaMg (1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin) or placebo (PL) in a double-blinded manner. NCI-CTC, an oxaliplatin-specific sNT scale and patient-reported outcome (PRO) questionnaires were used to differentially assess the effect of CaMg on acute (effect on sNT on days 1–4 after oxaliplatin) and chronic sNT (area between curves over whole course of therapy). Results: A total of 102 pts (50 CaMg, 52 PL; 96 mFOLFOX6, 6 FOLFOX4) were available for analysis. Apart from a strong reduction in muscle cramps with CaMg (p=0.002), no difference was found between CaMg and PL in PRO with regard to items reflecting acute sNT (e.g. sensitivity to cold, swallowing of cold liquids, throat discomfort) on days 1–4 after oxaliplatin of any treatment cycle. In contrast, CaMg was able to significantly reduce cumulative sNT in form of numbness in fingers (p=0.02), impaired ability to button shirts (p=0.05), tingling in fingers (p=0.06), and muscle cramps over the course of therapy (p=0.01). Conclusions: In our phase III, placebo-controlled trial, CaMg was able to significantly reduce chronic, cumulative sNT related to oxaliplatin as evaluated by specific PRO questionnaires. No effect was noted on phenomena associated with acute sNT. CaMg can be recommended as neuroprotectant against oxaliplatin-related chronic sNT, oxaliplatin's dose-limiting toxicity. [Table: see text]
Collapse
Affiliation(s)
- A. Grothey
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - D. A. Nikcevich
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - J. A. Sloan
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - J. W. Kugler
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - P. T. Silberstein
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - T. Dentchev
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - D. B. Wender
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - H. E. Windschilt
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - X. Zhao
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| | - C. L. Loprinzi
- Mayo Clinic Rochester, Rochester, MN; St Mary's Duluth Clinic, Duluth, MN; llinois Cancer Care, Peoria, IL; Creighton Hem Onc, Omaha, NE; Altru Health Systems, Grand Forks, ND; Siouxland Hematology-Oncology Associates, Sioux City, IA; CentraCare Clinic, St Cloud, MN
| |
Collapse
|